Fundraising FoxHM Venture Partners
Venture capitalSan Francisco · Seed–Growth · 7 people tracked
Find your way into HM Venture Partners
Sign up to see every warm intro you have to HM Venture Partners
- Paths you didn't know you had: your email and LinkedIn already hold routes to the HM Venture Partners team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
HM Venture Partners focuses on healthcare, investing in biotech and medtech companies globally and across all stages. It aims to help early- and growth-stage healthcare companies accelerate development by leveraging its team's deep domain expertise and an extensive ecosystem of academic institutions, physician networks, and industry experts. This network provides proprietary deal flow, clinical trial site access, and cross-border business development, particularly bridging the US and Chinese markets. The firm emphasizes identifying breakthrough innovations that address significant unmet medical needs and applies cycle-tested, flexible financing strategies to structure favorable transactions and create value. Its most recent fund, HM Healthcare Fund I, primarily targets healthcare breakthroughs in the US.
Source: firm website, verified Sep 26, 2026.
Team · 7 people
from the firm's website & public directories
What they invest in
from 24 of 30 portfolio companiesHealthtech ×18Biotech ×16Medical Devices ×13Digital Health ×4AI & Machine Learning ×2Deep Tech ×2FemTech ×2EdTech ×1
HQs:United States×14China×3Germany×1Denmark×1
Who they back
founder profiles across 14 portfolio companiesFounding team size:solo founder×92 founders×33 founders×14+ founders×1
Investments · 30 tracked
founders shown can be your intro pathBy year:2025 · 12023 · 12020 · 12017 · 14 dated
Sagimet is a clinical-stage biopharmaceutical company developing therapies targeting fatty acid synthase (FASN) for metabolic diseases and oncology.
BiotechDigital HealthHealthtechMenlo Park, US
Rekha Hemrajani(Executive Officer)inMerdad Parsey(Executive Officer, Director)inDavid Happel(Chief Executive Officer & Director)Andreas Grauer(Chief Medical Officer)inThierry Chauche(Chief Financial Officer)inMarie O'Farrell(Chief Scientific Officer)in
Co-investorsAltium CapitalKleiner PerkinsNew Enterprise Associates (NEA)BAM ElevateBiotechnology Value FundBlue Owl Capital+1 more
Arthrosi Therapeutics is a clinical-stage biopharmaceutical company developing treatments for gout, an inflammatory arthritis condition.
BiotechDigital HealthMedical DevicesSan Diego, US
Litain Yeh(Co-Founder & Chief Executive Officer)inShunqi Yan(Co-Founder & Chief Operating Officer)Robert Orr(Executive Officer, Director, Promoter)Yiwei Zong(Director)Jianfeng Fang(Director)
BoardZhang Mingyuan(Director)
Co-investorsMaxpro VenturesHighlight Capital
BioNTech is a biotechnology company developing immunotherapies that use the body's immune system, combining multiple therapeutic modalities and biological targets to treat cancer, infectious diseases, and other serious conditions.
BiotechHealthtechMainz, DE
Ozlem Tureci(Executive Officer)Ugur Sahin(Executive Officer)inSierk Poetting(Executive Officer)inSean Marett(Executive Officer)inRyan Richardson(Executive Officer)inUğur Şahin(Founder)in
Co-investorsManta Ray VenturesMIG Capital AGOnsight VenturesPfizer Venture InvestmentsSalviaAndreessen Horowitz
Coherent Biopharma (Tongyi Pharmaceutical) is a biopharmaceutical company developing its proprietary Bi-targeting XDC (bi-XDC) conjugate drug platform to make previously undruggable targets treatable, with a focus on oncology.
BiotechDeep TechHealthtech
Baohua Huang(Founder & CEO)
GenFleet is a biopharmaceutical company developing novel drug therapies focused on RAS targeting and antibody-drug conjugates (ADCs) to address unmet clinical needs in cancer and other serious diseases.
AI & Machine LearningBiotechHealthtechMedical DevicesBeijing, CN
Qiang LU(Founder)in
Board吕强兰炯
Co-investorsPan-Lin Capital
GIE Medical is a clinical-stage medical device company developing the ProTractX3, a drug-coated balloon for treating benign strictures of the esophagus and bowel.
BiotechHealthtechMedical DevicesPlymouth, US
Lixiao Wang(Founder & Chief Executive Officer)inIan Schorn(Chief Operational Officer)inJames Ness(Chief Financial Officer)Harrison Malinoff(VP of Operations and Quality)Dave Hendrickson(VP of Research & Development)Drew McClure(VP of Market Development)in
HuidaGene develops CRISPR and RNA-guided gene editing technologies for therapeutic applications in neurology, ophthalmology, otology, myology, and hepatology.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesShanghai, CN
Hui Yang(Co-Founder and Chief Scientific Advisor)
Immunotherapy oncology company engineering technologies to activate the immune system; acquired by Merck in February 2019 for $0.3B.
BiotechHealthtechMedical DevicesSeattle, US
David Baltimore(Director)Carlos V. Paya(Executive Officer, Director)Stephen R. Brady(Executive Officer)inJan Henrik ter Meulen(Executive Officer)Paul Rickey(Executive Officer)inWayne Gombotz(Executive Officer)in
Co-investorsAisling CapitalAtlas VentureOUP (Osage University Partners)Sanderling VenturesSanofi VenturesSPRINGROCK VENTURES+4 more
KBP is a biotechnology research and development organization that discovers and develops new therapies for unmet medical needs.
Biotech
Co-investorsBay City Capital
Melodi Health is a medical device company focused on breast reconstruction and breast procedures, developing implantable combination devices with expertise in infection control and plastic reconstructive surgery.
FemTechHardwareHealthtechMedical DevicesMinneapolis, US
Sarah Worrell(Co-founder & Chief Executive Officer)inMichele Hilmer(Chief Strategy Officer)Hunter Moyer, MD(Chief Medical Officer)Kaitlyn Roth(VP Operations)inMatthew Hemsley(Director)Arikha Moses(Director)
Co-investorsEngage Venture PartnersSoutheast Minnesota Capital Fund
Devices for fecal incontinence
HealthtechStewartville, US
David A. Jonas(Executive Officer, Director)Philip Conway(Executive Officer, Director)Sarah L. Grinde(Executive Officer, Director)in
BoardAnthony Conway(Director)
Co-investorsSoutheast Minnesota Capital Fund
Minnesota Medical Technologies develops and manufactures continence care products, specifically fecal incontinence management devices for individual patients.
Digital HealthHealthtechMedical DevicesStewartville, US
Philip J Conway(Executive Vice President – Operations (Founder))Sarah L Grinde(VP Marketing and Research & Development (Founder))Anthony J Conway(Chairman of the Board (Founder))Lonnie M Boe(Executive Secretary/Office Manager (Founder))
Co-investorsSoutheast Minnesota Capital Fund
Neurotronic is developing Neuviant Multi-organ Denervation (MDN), an investigational catheter-based therapy that delivers ethanol to overactive sympathetic nerves near the kidneys and liver to lower blood sugar and blood pressure.
Newswise is a news distribution platform and press release service that connects journalists, public relations professionals, and the public with research news and expert sources across medical, science, life, and business sectors.
Marketing TechMedia & EntertainmentSaaS
Roger Johnson(Founder)inJessica Johnsonin
Novo Nordisk is a pharmaceutical company that develops and markets treatments for conditions including diabetes, obesity/weight management, and haemophilia, with products such as GLP-1 therapies.
BiotechHealthtechCopenhagen, DK
Co-investorsNovo Holdings
OncoC4 is a clinical-stage biopharmaceutical company developing immunotherapy treatments for cancer patients, based on research by its immunologist founders.
BiotechHealthtechRockville, US
Yang Liu(Co-founder)inPan Zheng(Co-founder)inMartin Devenport(Executive Officer)Michael Flaschen(Director)
Co-investors3E Bioventures Capital
First-in-class biologic drug targeting the CD24-Siglec innate immunity signaling pathway.
BiotechRockville, US
Pan Zheng(Executive Officer)Yang Liu(Executive Officer, Director)Martin Devenport(Executive Officer)
BoardMiao Hong(Director)Karen Liu(Director)inKun-Liang Guan(Director)
Co-investors3E Bioventures Capital
Developer of VT-X7 for the treatment of periprosthetic joint infection.
BiotechDallas, US
David Thompson(Executive Officer, Director)inBrian de Beaubien(Executive Officer, Director)Renee Ryan(Director)Jude Paganelli(Executive Officer, Director)
BoardMartin Sands(Director)Judson Cooper(Director)
Osteal Therapeutics is a clinical-stage pharmaceutical company developing novel treatments for orthopedic infections, particularly periprosthetic joint infections.
BiotechDigital HealthHealthtechMedical Devices
Brian de Beaubien, MD(Co-Founder & Chief Medical Officer)David Thompson(Chairman & CEO)in
UC Davis is a public tier-one research university located in Davis, California, with additional campuses and centers including UC Davis Health in Sacramento and marine and environmental research labs.
EdTechDavis, US
Co-investorsDigitalDx VenturesThe March Group
Urotronic develops drug-coated balloons for interventional urology, including the Optilume products for treating benign prostatic hyperplasia (BPH) and urethral strictures.
HealthtechMedical DevicesPlymouth, US
Junfeng Wang(Director)David Perry(Executive Officer, Director)Tan Ching(Director)Hui Hu(Director, Promoter)Lixiao Wang(Director, Promoter)Doug Kohrs(Director)
Co-investorsEnterprise IrelandGilde HealthcareIreland Strategic Investment FundLegend CapitalLightstone VenturesMVM Life Science Partners+1 more
Verve Medical is developing the Verve RPD System, an investigational device for renal pelvic denervation—a minimally invasive catheter-based procedure that uses radiofrequency energy to disrupt overactive kidney nerves to lower blood pressure.
HealthtechMedical DevicesSanta Barbara, US
Terry Buelna(Chief Executive Officer/President/CFO)in
BoardWayne Wu(Director)
Zepto develops a targeted liquid biopsy platform for infectious disease diagnostics, offering plasma-based molecular testing through its CLIA reference laboratory and an integrated sample-to-result platform for use in hospital laboratories.
BiotechHealthtechMedical Devices
Yongyong Zhang(Founder)in
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
GIEKBPMedbotsurgicalRestoramedicalSobi completes acquisition of Arthrosi Therapeutics
Exits · 3
1 IPOs · 2 acquisitions · showing 2Sagimet BiosciencesNASDAQ: SGMTKBPacq. by Novo Nordisk
Portfolio news
latest coverage across their companies
Sagimet Biosciences · manilatimes.net · Sep 2, 2026
Arthrosi · finsmes.com · Oct 8, 2025
OncoC4 · biospace.com · Oct 2, 2025
Frequently asked questions
- How many investments has HM Venture Partners made?
- HM Venture Partners has 30 tracked investments, 3 of which have exited, including 1 dated in the last 24 months.
- What stage does HM Venture Partners invest at?
- HM Venture Partners invests at the Seed, Series A, Series B, Series C, Growth stages.
- What sectors does HM Venture Partners focus on?
- HM Venture Partners focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is HM Venture Partners located?
- HM Venture Partners is headquartered in San Francisco, US.
- Does HM Venture Partners lead rounds?
- Yes, HM Venture Partners leads investment rounds.
- Who does HM Venture Partners co-invest with?
- HM Venture Partners most often shares deals with Southeast Minnesota Capital Fund, 3E Bioventures Capital, Atlas Venture, among 21 tracked co-investors.
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.